You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

41 Results
Guidelines and Advice
Status: Education and Information
ID: GL-C50-23-V1
Version: 2
Dec 2015
Drug Safety & Advice
Jul 2015
Statistical Reports
Jul 2015
Statistical Reports
Mar 2015
Guidelines and Advice
Status: Current
ID: GL-C50-17
Jan 2015
Guidelines and Advice
Status: Current
ID: GL-C50-18
Jan 2015
Guidelines and Advice
Status: Current
ID: GL-C50-21
Jul 2015
Guidelines and Advice
Status: Current
ID: GL-C50-20
May 2015
Drug
Other Name(s): Provera® (multiple brands available)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2015
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
riTUXimab (subcut),
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
CISplatin,
cytarabine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2020
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lenvatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2020
Guidelines and Advice
Status: Current
ID: GL-C50-19
Jan 2015

Pages